RIKEN (the Institute of Physical and Chemical Research) in late February asked the health and welfare ministry for permission to carry out a clinical study that will use induced pluripotent (iPS) cells to treat an eye disease.

If everything goes smoothly, the treatment will be carried out early next year. In examining the request, the ministry must take utmost care to ensure safety in the clinical study — the most important thing for the clinical study.

Unable to view this article?

This could be due to a conflict with your ad-blocking or security software.

Please add japantimes.co.jp and piano.io to your list of allowed sites.

If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.

We humbly apologize for the inconvenience.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.